Selhání léčby první linie a nesnášenlivost linie druhé aneb co dál, když oba dostupné inhibitory tyrosinkinázy 2. generace selhávají
| Title in English | First-line treatment failure and second-line intolerance or what to do if both available 2nd generation tyrosine kinase inhibitors fail |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Hematology is one of the traditional components of internal medicine. However, especially the development of hematooncology in recent decades has made hematology a very complex and demanding field with a major societal impact. In addition, hematology and hematooncology are evolving extremely rapidly. This concerns both the changes in the classification of a number of nosological units and, in particular, the rapid introduction of new substances into hematooncological treatment. Advances in diagnosis, and especially targeted and biological treatment, bring new hope to many patients. However, these new therapeutic options are not always fully exploited in practice. |